How Long Does Dissociation Last After Spravato?
Spravato (esketamine nasal spray) commonly causes dissociation, a feeling of detachment from reality, during and shortly after administration. This side effect typically peaks within 40 minutes and resolves within 1-2 hours for most patients, though it can last up to 4 hours in some cases.[1][2]
Patients receive Spravato under medical supervision in a clinic, where vital signs and mental status are monitored until dissociation fully clears, often requiring a 2-hour observation period post-dose.[1]
What Does Dissociation Feel Like on Spravato?
Users report perceptual changes like distorted sense of time, space, or body image, sometimes with visual distortions or a dream-like state. It's dose-related and more intense with higher doses (56mg or 84mg).[2][3]
How Long Until You Can Drive or Work After Dissociation Clears?
Driving or operating machinery is prohibited on dosing day. Effects like dissociation, sedation, and cognitive impairment can persist up to 24 hours, so patients need a ride home and should avoid responsibilities until the next day.[1][4]
Why Does Dissociation Happen and How Is It Managed?
Esketamine blocks NMDA receptors in the brain, disrupting glutamate signaling and causing dissociative effects similar to ketamine. Clinicians manage it by lowering doses for sensitive patients, providing a calm environment, and monitoring closely. Severe cases are rare but may require intervention.[2][3]
Does Dissociation Get Better Over Time With Repeated Doses?
Tolerance develops with ongoing treatment (twice weekly initially, then maintenance). Many patients experience shorter, milder dissociation after the first few doses.[1][5]
Factors That Affect Dissociation Duration
Higher body weight, first-time use, or concurrent meds (like benzodiazepines) can prolong it. Women and older adults may feel stronger effects.[3]
[1]: Spravato Prescribing Information, Janssen Pharmaceuticals, https://www.spravatohcp.com/static/prescribing-information.pdf
[2]: FDA Label for Spravato, https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/211243s004lbl.pdf
[3]: Clinical Study Data on Esketamine (TRANSFORM-2 Trial), Journal of Clinical Psychiatry, 2019
[4]: Spravato REMS Program Guidelines, https://www.spravatorems.com/
[5]: Long-term Safety Data, American Journal of Psychiatry, 2020